LEC Proliferation in Vivo and In-vitro

Sponsor
Prim. Prof. Dr. Oliver Findl, MBA (Other)
Overall Status
Unknown status
CT.gov ID
NCT03857685
Collaborator
(none)
40
1
24
1.7

Study Details

Study Description

Brief Summary

Investigate the proliferative capacity of individual lens epithelium capsule specimens in vitro and correlate it to the risk of developing PCO

Condition or Disease Intervention/Treatment Phase
  • Procedure: In-vitro model

Detailed Description

Cataract, the clouding of the eye's lens, is still the leading cause of blindness worldwide. Until now surgery is the only therapy available for the disease. Cataract surgery is nowadays considered a safe and efficient therapy. However, one of the most frequent complications of cataract surgery is posterior capsule opacification (PCO), which results in diminished postoperative visual acuity. PCO occurs due to a robust wound-healing response, where remaining lens epithelial cells in the capsular bag start to migrate and proliferate.

The lens capsule is divided into an anterior, an equatorial, and a posterior region. The anterior and the equatorial region consist of a single layer of cuboidal epithelial cells, whilst the posterior region is formed of fibers. In the adult lens proliferation occurs almost exclusively in the equatorial region and although the central part of the lens epithelium exhibits very low mitotic activity, it was shown in experiments that cell in this area are also stem cells. There are three possible reasons for the generation of PCO: intraoperative factors (dependening on the amount of remaining cells in the capsular bag), intraocular lens factors, and interpersonal factor (patient-specific factors).

Aim of this study is the generation of an in-vitro model of posterior capsule opacification. Therefore, the investigators will analyse the proliferative capacity of lens epithelial cells on the lens capsule, which is removed during cataract surgery, in a cell culture model. The investigators then compare the proliferative capacity between young and old patients, between both eyes of the same patient, and in different forms of cataract.

Study Design

Study Type:
Observational
Anticipated Enrollment :
40 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Bilateral and Age-dependent Differences in Posterior Capsule Opacification in Vivo Compared to an In-vitro Mode
Actual Study Start Date :
Jan 1, 2019
Anticipated Primary Completion Date :
May 1, 2020
Anticipated Study Completion Date :
Jan 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Proliferation in an in-vitro model

An in-vitro model is used to study lens epithelial cell proliferation

Procedure: In-vitro model
In-vitro model of posterior capsule opacification by culturing the lens capsule

Outcome Measures

Primary Outcome Measures

  1. Amount of proliferation of lens epithelial cells (LECs) in-vitro compared to in vivo in the same patient [24 months]

    Proliferation of LECs in-vitro will be measured as area/mm2 and correlated with ratings of posterior capsular opacification in vivo using a scale from 0 to 10

Secondary Outcome Measures

  1. Amount of proliferation of LECs in-vitro in young and older patients [24 months]

    Proliferation of LECs in-vitro will be measured as area/mm2 and compared between older and younger individuals

  2. Amount of proliferation of LECs in-vitro between different forms of cataract [24 months]

    Proliferation of LECs in-vitro will be measured as area/mm2 and compared between the different forms of cataract (cortical, nuclear, posterior subcapsular)

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 105 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age-related cataract.

  • Patients in the age group of 21 years and older.

  • Patients with uncomplicated cataract.

  • Patients without any relevant systemic or ocular morbidity.

  • Patients with well dilating pupils.

  • Written informed consent prior to any study specific action.

Exclusion Criteria:
  • Patients with complicated cataract.

  • Patients with big differences in LOCS scale between the two eyes.

  • Patients having corneal pathology.

  • Patients with any form of ocular inflammation.

  • Patients with glaucoma, retinal pathologies.

  • Patients with traumatic cataracts, subluxated and dislocated lens, prior h/o ocular surgery, pseudoexfoliation.

  • Any intraoperative complications like posterior capsule rupture.

  • In case of pregnancy (pregnancy test will be taken preoperatively in women of reproductive age).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Vienna Institute for Research in Ocular Surgery (VIROS) Vienna Austria 1140

Sponsors and Collaborators

  • Prim. Prof. Dr. Oliver Findl, MBA

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Prim. Prof. Dr. Oliver Findl, MBA, Principal Investigator, Vienna Institute for Research in Ocular Surgery
ClinicalTrials.gov Identifier:
NCT03857685
Other Study ID Numbers:
  • Proliferation
First Posted:
Feb 28, 2019
Last Update Posted:
Mar 16, 2020
Last Verified:
Mar 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Prim. Prof. Dr. Oliver Findl, MBA, Principal Investigator, Vienna Institute for Research in Ocular Surgery
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 16, 2020